Laura Aitken

List of Publications by Year
in descending order

18	428	687363 13	839539 18
papers	citations	h-index	g-index

18	18	18	537
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tacrine â€“ Benzothiazoles: Novel class of potential multitarget anti-AlzheimeÅ•s drugs dealing with cholinergic, amyloid and mitochondrial systems. Bioorganic Chemistry, 2021, 107, 104596.	4.1	17
2	Willin/FRMD6: A Multi-Functional Neuronal Protein Associated with Alzheimerâ€™s Disease. Cells, 2021, 10, 3024.	4.1	6
3	Neuroprotective actions of leptin facilitated through balancing mitochondrial morphology and improving mitochondrial function. Journal of Neurochemistry, 2020, 155, 191-206.	3.9	13
4	Benzothiazolyl Ureas are Low Micromolar and Uncompetitive Inhibitors of 17Î²-HSD10 with Implications to Alzheimerâ€™s Disease Treatment. International Journal of Molecular Sciences, 2020, 21, 2059.	4.1	14
5	Novel Benzothiazole-based Ureas as 17Î²-HSD10 Inhibitors, A Potential Alzheimerâ€™s Disease Treatment. Molecules, 2019, 24, 2757.	3.8	20
6	1-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 665-670.	5.2	26
7	In Vitro Assay Development and HTS of Small-Molecule Human ABAD/17Î²-HSD10 Inhibitors as Therapeutics in Alzheimerâ€™s Disease. SLAS Discovery, 2017, 22, 676-685.	2.7	14
8	Synthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alzheimerâ€™s disease treatment. Bioorganic and Medicinal Chemistry, 2017, 25, 1143-1152.	3.0	45
9	6-Benzothiazolyl Ureas, Thioureas and Guanidines are Potent Inhibitors of ABAD/17Î²-HSD10 and Potential Drugs for Alzheimer"s Disease Treatment: Design, Synthesis and in vitro Evaluation. Medicinal Chemistry, 2017, 13, 345-358.	1.5	22
10	6-benzothiazolyl ureas, thioureas and guanidines are potent inhibitors of ABAD/17Î²-HSD10 and potential drugs for Alzheimer's disease treatment: Design, synthesis and in vitro evaluation. Medicinal Chemistry, 2017, , .	1.5	4
11	Morphologyâ€Specific Inhibition of Î²â€Amyloid Aggregates by 17Î²â€Hydroxysteroid Dehydrogenase Type 10. ChemBioChem, 2016, 17, 1029-1037.	2.6	12
12	Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17Î²-HSD10 modulators for Alzheimerâ€™s disease treatment. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3675-3678.	2.2	29
13	Benzothiazoles - Scaffold of Interest for CNS Targeted Drugs. Current Medicinal Chemistry, 2015, 22, 730-747.	2.4	27
14	A Direct Interaction Between Mitochondrial Proteins and Amyloid-β Peptide and its Significance for the Progression and Treatment of Alzheimer’s Disease. Current Medicinal Chemistry, 2015, 22, 1056-1085.	2.4	32
15	Is Amyloid Binding Alcohol Dehydrogenase a Drug Target for Treating Alzheimerâ€™s Disease?. Current Alzheimer Research, 2013, 10, 21-29.	1.4	20
16	Is amyloid binding alcohol dehydrogenase a drug target for treating Alzheimer's disease?. Current Alzheimer Research, 2013, 10, 21-9.	1.4	28
17	Mitochondrial Î²-amyloid in Alzheimer's disease. Biochemical Society Transactions, 2011, 39, 868-873.	3.4	32
18	The consequences of mitochondrial amyloid Î²-peptide in Alzheimer's disease. Biochemical Journal, 2010, 426, 255-270.	3.7	67